E
Sangamo Therapeutics, Inc.
SGMO
$0.6532
$0.083114.58%
E
Sell
8/15/2024Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 8/15/2024 due to a decline in the valuation index and solvency index. The quick ratio declined from 1.37 to 0.73.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 8/15/2024 due to a decline in the valuation index and solvency index. The quick ratio declined from 1.37 to 0.73.
D
Sell
7/31/2024Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 7/31/2024 due to an increase in the volatility index.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 7/31/2024 due to an increase in the volatility index.
E
Sell
5/30/2024Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 5/30/2024 due to a major decline in the growth index, solvency index and volatility index. Total revenue declined 76.44% from $2.04M to $481, and the quick ratio declined from 1.72 to 1.37.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 5/30/2024 due to a major decline in the growth index, solvency index and volatility index. Total revenue declined 76.44% from $2.04M to $481, and the quick ratio declined from 1.72 to 1.37.
D
Sell
4/11/2024Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 4/11/2024 due to an increase in the volatility index.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 4/11/2024 due to an increase in the volatility index.
E
Sell
3/27/2024Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 3/27/2024 due to a decline in the growth index and volatility index. Total revenue declined 78.27% from $9.4M to $2.04M, and operating cash flow declined 6.86% from -$47.29M to -$50.54M.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 3/27/2024 due to a decline in the growth index and volatility index. Total revenue declined 78.27% from $9.4M to $2.04M, and operating cash flow declined 6.86% from -$47.29M to -$50.54M.
D
Sell
3/6/2024Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 3/6/2024 due to a noticeable increase in the growth index and volatility index. Total revenue increased 37.5% from $6.84M to $9.4M, operating cash flow increased 22.1% from -$60.71M to -$47.29M, and EBIT increased 14.7% from -$72.23M to -$61.61M.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 3/6/2024 due to a noticeable increase in the growth index and volatility index. Total revenue increased 37.5% from $6.84M to $9.4M, operating cash flow increased 22.1% from -$60.71M to -$47.29M, and EBIT increased 14.7% from -$72.23M to -$61.61M.
E
Sell
4/21/2023Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index and total return index.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index and total return index.
D
Sell
3/31/2023Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 3/31/2023 due to an increase in the volatility index and valuation index.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 3/31/2023 due to an increase in the volatility index and valuation index.
E
Sell
3/16/2023Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 3/16/2023 due to a decline in the volatility index and total return index.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 3/16/2023 due to a decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 6.4% from -$53.62M to -$57.05M, and EBIT declined 0.91% from -$54.89M to -$55.39M.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 6.4% from -$53.62M to -$57.05M, and EBIT declined 0.91% from -$54.89M to -$55.39M.
D
Sell
2/9/2023Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
8/8/2022Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D from D- on 8/8/2022 due to an increase in the growth index and volatility index. Operating cash flow increased 8.46% from -$58.98M to -$53.99M, total revenue increased 4.06% from $28.23M to $29.38M, and earnings per share increased from -$0.3008 to -$0.2914.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D from D- on 8/8/2022 due to an increase in the growth index and volatility index. Operating cash flow increased 8.46% from -$58.98M to -$53.99M, total revenue increased 4.06% from $28.23M to $29.38M, and earnings per share increased from -$0.3008 to -$0.2914.
D
Sell
5/31/2022Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 05/31/2022.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 05/31/2022.
E
Sell
5/13/2022Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 5/13/2022 due to a decline in the total return index and volatility index.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/6/2022Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D- from D on 5/6/2022 due to a decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.2573 to -$0.3008, EBIT declined 13.44% from -$39.9M to -$45.26M, and operating cash flow declined 11.88% from -$52.71M to -$58.98M.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D- from D on 5/6/2022 due to a decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.2573 to -$0.3008, EBIT declined 13.44% from -$39.9M to -$45.26M, and operating cash flow declined 11.88% from -$52.71M to -$58.98M.
D
Sell
5/4/2022Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 3.28 to 2.99.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 3.28 to 2.99.
D
Sell
11/23/2021Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D from D- on 11/23/2021.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D- from D on 11/8/2021 due to a major decline in the total return index, volatility index and solvency index. The quick ratio declined from 3.92 to 3.28.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D- from D on 11/8/2021 due to a major decline in the total return index, volatility index and solvency index. The quick ratio declined from 3.92 to 3.28.
D
Sell
2/26/2021Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 2/26/2021 due to a significant decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.011 to -$0.2869, EBIT declined 1,073.52% from -$3.7M to -$43.43M, and operating cash flow declined 112.99% from $33.07M to -$4.3M.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 2/26/2021 due to a significant decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.011 to -$0.2869, EBIT declined 1,073.52% from -$3.7M to -$43.43M, and operating cash flow declined 112.99% from $33.07M to -$4.3M.
D
Sell
2/25/2021Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 2/25/2021 due to a noticeable increase in the total return index, valuation index and volatility index.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 2/25/2021 due to a noticeable increase in the total return index, valuation index and volatility index.
D
Sell
12/23/2020Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 12/23/2020 due to a decline in the valuation index.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 12/23/2020 due to a decline in the valuation index.
D
Sell
12/8/2020Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 12/8/2020 due to an increase in the solvency index, volatility index and valuation index.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 12/8/2020 due to an increase in the solvency index, volatility index and valuation index.
D
Sell
11/19/2020Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 11/19/2020 due to a decline in the growth index, volatility index and valuation index. Operating cash flow declined 79.33% from $159.99M to $33.07M.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 11/19/2020 due to a decline in the growth index, volatility index and valuation index. Operating cash flow declined 79.33% from $159.99M to $33.07M.
D
Sell
8/6/2020Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 8/6/2020 due to a major increase in the growth index. Operating cash flow increased 946.97% from -$18.89M to $159.99M, total revenue increased 64.83% from $13.08M to $21.55M, and earnings per share increased from -$0.3697 to -$0.26.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 8/6/2020 due to a major increase in the growth index. Operating cash flow increased 946.97% from -$18.89M to $159.99M, total revenue increased 64.83% from $13.08M to $21.55M, and earnings per share increased from -$0.3697 to -$0.26.
D
Sell
10/3/2019Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 10/3/2019 due to a decline in the total return index.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 10/3/2019 due to a decline in the total return index.
D
Sell
8/8/2019Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 8/8/2019 due to an increase in the efficiency index, valuation index and growth index. Total revenue increased 117.42% from $8.07M to $17.55M, total capital increased 41.74% from $343.8M to $487.3M, and earnings per share increased from -$0.4121 to -$0.2648.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 8/8/2019 due to an increase in the efficiency index, valuation index and growth index. Total revenue increased 117.42% from $8.07M to $17.55M, total capital increased 41.74% from $343.8M to $487.3M, and earnings per share increased from -$0.4121 to -$0.2648.
D
Sell
1/30/2019Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 1/30/2019 due to a decline in the total return index and volatility index.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 1/30/2019 due to a decline in the total return index and volatility index.
D
Sell
1/11/2019Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 1/11/2019 due to an increase in the total return index.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 1/11/2019 due to an increase in the total return index.
D
Sell
12/6/2018Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 12/6/2018 due to a noticeable decline in the solvency index, growth index and total return index. Operating cash flow declined 122.54% from $122.44M to -$27.6M, and the quick ratio declined from 7.18 to 6.27.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 12/6/2018 due to a noticeable decline in the solvency index, growth index and total return index. Operating cash flow declined 122.54% from $122.44M to -$27.6M, and the quick ratio declined from 7.18 to 6.27.
D
Sell
8/9/2018Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 8/9/2018 due to an increase in the solvency index, valuation index and efficiency index. Total capital increased 112.69% from $182.37M to $387.87M, the quick ratio increased from 4.73 to 7.18, and net income increased 17.57% from -$20.19M to -$16.64M.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D on 8/9/2018 due to an increase in the solvency index, valuation index and efficiency index. Total capital increased 112.69% from $182.37M to $387.87M, the quick ratio increased from 4.73 to 7.18, and net income increased 17.57% from -$20.19M to -$16.64M.
D
Sell
11/13/2017Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 11/13/2017 due to a decline in the valuation index, growth index and efficiency index. Operating cash flow declined 127.62% from $56.79M to -$15.69M, total capital declined 3.81% from $194.04M to $186.65M, and EBIT declined 2.09% from -$12.77M to -$13.04M.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to D from D+ on 11/13/2017 due to a decline in the valuation index, growth index and efficiency index. Operating cash flow declined 127.62% from $56.79M to -$15.69M, total capital declined 3.81% from $194.04M to $186.65M, and EBIT declined 2.09% from -$12.77M to -$13.04M.
D
Sell
8/10/2017Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D- on 8/10/2017 due to a significant increase in the total return index, growth index and volatility index. Operating cash flow increased 534.21% from -$13.08M to $56.79M, total revenue increased 140.96% from $3.43M to $8.25M, and earnings per share increased from -$0.2342 to -$0.1722.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D+ from D- on 8/10/2017 due to a significant increase in the total return index, growth index and volatility index. Operating cash flow increased 534.21% from -$13.08M to $56.79M, total revenue increased 140.96% from $3.43M to $8.25M, and earnings per share increased from -$0.2342 to -$0.1722.
D
Sell
3/3/2017Upgraded
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 3/3/2017 due to an increase in the growth index, total return index and volatility index. Total revenue increased 216.05% from $2.82M to $8.92M, earnings per share increased from -$0.2686 to -$0.1361, and EBIT increased 48.82% from -$19.21M to -$9.83M.
Sangamo Therapeutics, Inc. (SGMO) was upgraded to D- from E+ on 3/3/2017 due to an increase in the growth index, total return index and volatility index. Total revenue increased 216.05% from $2.82M to $8.92M, earnings per share increased from -$0.2686 to -$0.1361, and EBIT increased 48.82% from -$19.21M to -$9.83M.
E
Sell
2/13/2017Downgrade
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 2/13/2017 due to a noticeable decline in the efficiency index, total return index and volatility index. Total capital declined 10.12% from $160.02M to $143.84M.
Sangamo Therapeutics, Inc. (SGMO) was downgraded to E+ from D- on 2/13/2017 due to a noticeable decline in the efficiency index, total return index and volatility index. Total capital declined 10.12% from $160.02M to $143.84M.
D
Sell
6/17/2016Downgrade
Sangamo Biosciences Inc. (SGMO) was downgraded to D- from D on 6/17/2016 due to a decline in the volatility index and valuation index.
Sangamo Biosciences Inc. (SGMO) was downgraded to D- from D on 6/17/2016 due to a decline in the volatility index and valuation index.
D
Sell
5/23/2016Upgraded
Sangamo Biosciences Inc. (SGMO) was upgraded to D from D- on 5/23/2016 due to an increase in the volatility index.
Sangamo Biosciences Inc. (SGMO) was upgraded to D from D- on 5/23/2016 due to an increase in the volatility index.
D
Sell
5/6/2016Downgrade
Sangamo Biosciences Inc. (SGMO) was downgraded to D- from D on 5/6/2016 due to a major decline in the volatility index, growth index and total return index. Operating cash flow declined 123.64% from -$9.1M to -$20.36M, total revenue declined 56.78% from $9.12M to $3.94M, and earnings per share declined from -$0.1997 to -$0.2344.
Sangamo Biosciences Inc. (SGMO) was downgraded to D- from D on 5/6/2016 due to a major decline in the volatility index, growth index and total return index. Operating cash flow declined 123.64% from -$9.1M to -$20.36M, total revenue declined 56.78% from $9.12M to $3.94M, and earnings per share declined from -$0.1997 to -$0.2344.
D
Sell
2/29/2016Downgrade
Sangamo Biosciences Inc. (SGMO) was downgraded to D from D+ on 2/29/2016 due to a noticeable decline in the growth index, total return index and efficiency index. Operating cash flow declined 35.88% from -$14.2M to -$9.1M, and total capital declined 5.46% from $203.56M to $192.44M.
Sangamo Biosciences Inc. (SGMO) was downgraded to D from D+ on 2/29/2016 due to a noticeable decline in the growth index, total return index and efficiency index. Operating cash flow declined 35.88% from -$14.2M to -$9.1M, and total capital declined 5.46% from $203.56M to $192.44M.
D
Sell
1/15/2016Downgrade
Sangamo Biosciences Inc. (SGMO) was downgraded to D+ from C- on 1/15/2016 due to a large decline in the total return index.
Sangamo Biosciences Inc. (SGMO) was downgraded to D+ from C- on 1/15/2016 due to a large decline in the total return index.
C
Hold
12/31/2015Upgraded
Sangamo Biosciences Inc. (SGMO) was upgraded to C- from D+ on 12/31/2015 due to an increase in the total return index, efficiency index and valuation index. Total capital increased 1.81% from $199.94M to $203.56M.
Sangamo Biosciences Inc. (SGMO) was upgraded to C- from D+ on 12/31/2015 due to an increase in the total return index, efficiency index and valuation index. Total capital increased 1.81% from $199.94M to $203.56M.
D
Sell
7/22/2015Downgrade
Sangamo Biosciences Inc. (SGMO) was downgraded to D+ from C- on 7/22/2015 due to a significant decline in the volatility index.
Sangamo Biosciences Inc. (SGMO) was downgraded to D+ from C- on 7/22/2015 due to a significant decline in the volatility index.
C
Hold
5/15/2015Upgraded
Sangamo Biosciences Inc. (SGMO) was upgraded to C- from D+ on 5/15/2015 due to an increase in the valuation index and volatility index.
Sangamo Biosciences Inc. (SGMO) was upgraded to C- from D+ on 5/15/2015 due to an increase in the valuation index and volatility index.
D
Sell
4/30/2015Downgrade
Sangamo Biosciences Inc. (SGMO) was downgraded to D+ from C- on 4/30/2015 due to a major decline in the growth index and solvency index. Operating cash flow declined 11.76% from -$2.71M to -$2.39M, and total revenue declined 9.77% from $14.95M to $13.49M.
Sangamo Biosciences Inc. (SGMO) was downgraded to D+ from C- on 4/30/2015 due to a major decline in the growth index and solvency index. Operating cash flow declined 11.76% from -$2.71M to -$2.39M, and total revenue declined 9.77% from $14.95M to $13.49M.
C
Hold
2/27/2015Upgraded
Sangamo Biosciences Inc. (SGMO) was upgraded to C- from D+ on 2/27/2015 due to a major increase in the growth index, efficiency index and solvency index. Total revenue increased 20.42% from $12.42M to $14.95M, and the quick ratio increased from 8.78 to 9.09.
Sangamo Biosciences Inc. (SGMO) was upgraded to C- from D+ on 2/27/2015 due to a major increase in the growth index, efficiency index and solvency index. Total revenue increased 20.42% from $12.42M to $14.95M, and the quick ratio increased from 8.78 to 9.09.
D
Sell
2/20/2015Downgrade
Sangamo Biosciences Inc. (SGMO) was downgraded to D+ from C- on 2/20/2015 due to a major decline in the volatility index, total return index and valuation index.
Sangamo Biosciences Inc. (SGMO) was downgraded to D+ from C- on 2/20/2015 due to a major decline in the volatility index, total return index and valuation index.
C
Hold
7/31/2014Downgrade
Sangamo Biosciences Inc. (SGMO) was downgraded to C- from C on 7/31/2014 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 175.35% from $11.38M to -$8.57M, earnings per share declined from -$0.1198 to -$0.1027, and the quick ratio declined from 13.36 to 11.96.
Sangamo Biosciences Inc. (SGMO) was downgraded to C- from C on 7/31/2014 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 175.35% from $11.38M to -$8.57M, earnings per share declined from -$0.1198 to -$0.1027, and the quick ratio declined from 13.36 to 11.96.
C
Hold
7/24/2014Upgraded
Sangamo Biosciences Inc. (SGMO) was upgraded to C from C- on 7/24/2014 due to an increase in the valuation index and volatility index.
Sangamo Biosciences Inc. (SGMO) was upgraded to C from C- on 7/24/2014 due to an increase in the valuation index and volatility index.
C
Hold
5/29/2014Downgrade
Sangamo Biosciences Inc. (SGMO) was downgraded to C- from C on 5/29/2014 due to a decline in the valuation index.
Sangamo Biosciences Inc. (SGMO) was downgraded to C- from C on 5/29/2014 due to a decline in the valuation index.
C
Hold
5/14/2014Upgraded
Sangamo Biosciences Inc. (SGMO) was upgraded to C from C- on 5/14/2014 due to an increase in the volatility index and valuation index.
Sangamo Biosciences Inc. (SGMO) was upgraded to C from C- on 5/14/2014 due to an increase in the volatility index and valuation index.
C
Hold
5/9/2014Upgraded
Sangamo Biosciences Inc. (SGMO) was upgraded to C- from D+ on 5/9/2014 due to a major increase in the growth index, volatility index and valuation index. Total revenue increased 18.15% from $6.87M to $8.12M.
Sangamo Biosciences Inc. (SGMO) was upgraded to C- from D+ on 5/9/2014 due to a major increase in the growth index, volatility index and valuation index. Total revenue increased 18.15% from $6.87M to $8.12M.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
